0001193125-20-016154.txt : 20200128 0001193125-20-016154.hdr.sgml : 20200128 20200128085213 ACCESSION NUMBER: 0001193125-20-016154 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200128 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200128 DATE AS OF CHANGE: 20200128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 20551501 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 8-K 1 d879257d8k.htm 8-K 8-K
false 0000860730 0000860730 2020-01-28 2020-01-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 28, 2020

 

HCA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-11239

 

27-3865930

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

     

One Park Plaza, Nashville,

Tennessee

 

37203

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (615) 344-9551

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $.01 par value per share

 

HCA

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     

 

 


Item 2.02. Results of Operations and Financial Condition.

On January 28, 2020, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2019, the text of which is set forth as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

On January 28, 2020, the Company issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2019, the text of which is set forth as Exhibit 99.1.

Item 8.01. Other Events.

On January 28, 2020, the Company announced that its Board of Directors had authorized an additional share repurchase program for up to $2 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws from time to time in the open market, through privately negotiated transactions, or otherwise.

On January 28, 2020, the Company also announced that its Board of Directors had declared a quarterly cash dividend of $0.43 per share of the Company’s common stock. The dividend will be paid on March 31, 2020 to stockholders of record at the close of business on March 2, 2020.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit 99.1

   

Press Release, dated January 28, 2020.

       

Exhibit 104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HCA HEALTHCARE, INC.

     

 

/s/ William B. Rutherford

 

William B. Rutherford

Executive Vice President and Chief Financial Officer

Date: January 28, 2020

EX-99.1 2 d879257dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO   

LOGO

 

 

   FOR IMMEDIATE RELEASE
INVESTOR CONTACT:    MEDIA CONTACT:
Mark Kimbrough    Harlow Sumerford
615-344-2688    615-344-1851

HCA Reports Fourth Quarter 2019 Results

and Provides 2020 Guidance

Board Authorizes Additional $2 Billion Share Repurchase Program

and Increases Quarterly Dividend

Nashville, Tenn., January 28, 2020 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the fourth quarter ended December 31, 2019.

Key fourth quarter metrics (all percentage changes compare 4Q 2019 to 4Q 2018 unless otherwise noted):

 

   

Revenues totaled $13.523 billion

 

   

Net income attributable to HCA Healthcare, Inc. totaled $1.071 billion, or $3.09 per diluted share

 

   

Adjusted EBITDA totaled $2.738 billion

 

   

Cash flows from operating activities totaled $2.505 billion

 

   

Same facility admissions and same facility equivalent admissions increased 4.7 percent and 5.0 percent, respectively

Revenues in the fourth quarter of 2019 increased to $13.523 billion, compared to $12.274 billion in the fourth quarter of 2018. Net income attributable to HCA Healthcare, Inc. totaled $1.071 billion, or $3.09 per diluted share, compared to $1.064 billion, or $3.01 per diluted share, in the fourth quarter of 2018. Results for the fourth quarter of 2018 included gains on sales of facilities of $8 million, or $0.02 per diluted share. In the fourth quarter of 2018 we recorded a $67 million, or $0.19 per diluted share, favorable adjustment to our deferred tax assets and liabilities related to the impact of the Tax Cuts and Jobs Act.

For the fourth quarter of 2019, Adjusted EBITDA totaled $2.738 billion, compared to $2.508 billion in the fourth quarter of 2018. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

 

1


During the fourth quarter of 2018, the Company incurred additional expenses and experienced losses of revenues estimated at $31 million, or $0.07 per diluted share, associated with Hurricane Michael’s impact on our Florida panhandle facilities. This amount is prior to any potential insurance recoveries. Also, during the fourth quarter of 2018, the Company recorded a benefit of $49 million, or $0.11 per diluted share, from an insurance recovery related to Hurricane Harvey business interruption losses incurred during 2017.

Same facility admissions and same facility equivalent admissions increased 4.7 percent and 5.0 percent, respectively, in the fourth quarter of 2019 compared to the prior year period. Same facility emergency room visits increased 6.7 percent in the fourth quarter of 2019, compared to the prior year period. Same facility inpatient surgeries increased 2.1 percent, and same facility outpatient surgeries increased 1.8 percent in the fourth quarter of 2019, compared to the same period of 2018. Same facility revenue per equivalent admission increased 1.1 percent in the fourth quarter of 2019, compared to the fourth quarter of 2018.

Salaries and benefits, supplies and other operating expenses totaled $10.805 billion, or 79.8 percent of revenues, in the fourth quarter of 2019, compared to $9.770 billion, or 79.6 percent of revenues, in the fourth quarter of 2018.

Year Ended December 31, 2019

Revenues for the year ended December 31, 2019 totaled $51.336 billion, compared to $46.677 billion in the year ended December 31, 2018. Net income attributable to HCA Healthcare, Inc. was $3.505 billion, or $10.07 per diluted share, compared to $3.787 billion, or $10.66 per diluted share, for the year ended December 31, 2018. Results for the year ended December 31, 2019 include gains on sales of facilities of $18 million, or $0.04 per diluted share, and losses on retirement of debt of $211 million, or $0.47 per diluted share. Results for 2018 included gains on sales of facilities of $428 million, or $0.91 per diluted share, and losses on retirement of debt of $9 million, or $0.02 per diluted share.

For 2019, Adjusted EBITDA totaled $9.857 billion compared to $8.949 billion in 2018. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Balance Sheet and Cash Flows from Operations

As of December 31, 2019, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $621 million, total debt of $33.722 billion, and total assets of $45.058 billion. During the fourth quarter of 2019, capital expenditures totaled $1.274 billion, excluding acquisitions. Cash flows provided by operating activities in the fourth quarter totaled $2.505 billion, compared to $2.175 billion in the fourth quarter of 2018.

During the fourth quarter of 2019, the Company repurchased 2.069 million shares of its common stock at a cost of $272 million, and during the year ended December 31, 2019, repurchased 7.949 million shares of its common stock at a cost of $1.031 billion. The Company had $1.241 billion remaining under its existing repurchase authorization as of December 31, 2019.

Share Repurchase Program

The HCA Healthcare, Inc. Board of Directors has authorized an additional share repurchase program for up to $2 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws and may be made at management’s discretion from time to time in the open market, through privately negotiated transactions, or otherwise. The repurchase program has no time limit and may be suspended for periods or discontinued at any time.

 

2


Dividend

HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.43 per share on the Company’s common stock. The dividend will be paid on March 31, 2020 to stockholders of record at the close of business on March 2, 2020.

The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition and results of operations and contractual restrictions. Future dividends are expected to be funded by future cash flows from operations.

2020 Guidance

Today, HCA issued the following estimated guidance for 2020:

 

    

2020 Guidance Range

Revenues

   $53.5 to $55.5 billion

Adjusted EBITDA

   $10.25 to $10.65 billion

EPS (diluted)

   $11.30 to $12.10 per diluted share

Capital Expenditures

   $4.0 to $4.2 billion

The Company’s 2020 guidance contains a number of assumptions and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”

Annual Stockholders’ Meeting

The Company’s 2020 annual stockholders’ meeting will be held in Nashville, Tennessee on May 1, 2020 at 2:00 p.m. local time for stockholders of record as of March 9, 2020.

Earnings Conference Call

HCA will host a conference call for investors at 9:00 a.m. Central Standard Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed at https://event.webcasts.com/starthere.jsp?ei=1279390&tp_key=c73d4ed596 or through the Company’s Investor Relations web page at www.hcahealthcare.com.

 

3


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending December 31, 2020, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, (2) the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), including the effects of court challenges to, any repeal of, or changes to, the Affordable Care Act or additional changes to its implementation, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state or local laws or regulations affecting the health care industry, including single-payer proposals (often referred to as “Medicare for All”), (3) the effects related to the continued implementation of the sequestration spending reductions required under the Budget Control Act of 2011, and related legislation extending these reductions, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (4) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (5) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (6) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (7) the highly competitive nature of the health care business, (8) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (9) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (10) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (11) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (12) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (13) changes in accounting practices, (14) changes in general economic conditions nationally and regionally in our markets, (15) the emergence of and effects related to infectious diseases, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) potential adverse impact of known and unknown government

 

4


investigations, litigation and other claims that may be made against us, (21) the impact of potential cybersecurity incidents or security breaches, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology and the impact of interoperability requirements, (23) the impact of natural disasters, such as hurricanes and floods, or similar events beyond our control, (24) the effects of the 2017 Tax Cuts and Jobs Act, including potential legislation or interpretive guidance that may be issued by federal and state taxing authorities or other standard-setting bodies, and (25) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2018 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

 

5


HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

Fourth Quarter

(Dollars in millions, except per share amounts)

 

     2019     2018  
     Amount     Ratio     Amount     Ratio  

Revenues

   $ 13,523       100.0   $ 12,274       100.0

Salaries and benefits

     6,105       45.1       5,485       44.7  

Supplies

     2,232       16.5       2,002       16.3  

Other operating expenses

     2,468       18.2       2,283       18.6  

Equity in earnings of affiliates

     (20     (0.1     (4     —    

Depreciation and amortization

     694       5.2       581       4.8  

Interest expense

     438       3.2       446       3.6  

Gains on sales of facilities

     (1     —         (8     (0.1
  

 

 

   

 

 

   

 

 

   

 

 

 
     11,916       88.1       10,785       87.9  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     1,607       11.9       1,489       12.1  

Provision for income taxes

     334       2.5       244       2.0  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     1,273       9.4       1,245       10.1  

Net income attributable to noncontrolling interests

     202       1.5       181       1.4  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to HCA Healthcare, Inc.

   $ 1,071       7.9     $ 1,064       8.7  
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted earnings per share

   $ 3.09       $ 3.01    

Shares used in computing diluted earnings per share (millions)

     346.791         352.876    

Comprehensive income attributable to HCA Healthcare, Inc.

   $ 1,072       $ 1,044    
  

 

 

     

 

 

   

 

6


HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

For the Years Ended December 31, 2019 and 2018

(Dollars in millions, except per share amounts)

 

     2019     2018  
     Amount     Ratio     Amount     Ratio  

Revenues

   $ 51,336       100.0   $ 46,677       100.0

Salaries and benefits

     23,560       45.9       21,425       45.9  

Supplies

     8,481       16.5       7,724       16.5  

Other operating expenses

     9,481       18.5       8,608       18.5  

Equity in earnings of affiliates

     (43     (0.1     (29     (0.1

Depreciation and amortization

     2,596       5.0       2,278       4.9  

Interest expense

     1,824       3.6       1,755       3.8  

Gains on sales of facilities

     (18     —         (428     (0.9

Losses on retirement of debt

     211       0.4       9       —    
  

 

 

   

 

 

   

 

 

   

 

 

 
     46,092       89.8       41,342       88.6  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     5,244       10.2       5,335       11.4  

Provision for income taxes

     1,099       2.1       946       2.0  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     4,145       8.1       4,389       9.4  

Net income attributable to noncontrolling interests

     640       1.3       602       1.3  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to HCA Healthcare, Inc.

   $ 3,505       6.8     $ 3,787       8.1  
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted earnings per share

   $ 10.07       $ 10.66    

Shares used in computing diluted earnings per share (millions)

     348.226         355.303    

Comprehensive income attributable to HCA Healthcare, Inc.

   $ 3,426       $ 3,779    
  

 

 

     

 

 

   

 

7


HCA Healthcare, Inc.

Condensed Consolidated Balance Sheets

(Dollars in millions)

 

     December 31,     September 30,     December 31,  
     2019     2019     2018  

ASSETS

      

Current assets:

      

Cash and cash equivalents

   $ 621     $ 559     $ 502  

Accounts receivable

     7,380       7,131       6,789  

Inventories

     1,849       1,769       1,732  

Other

     1,346       1,310       1,190  
  

 

 

   

 

 

   

 

 

 

Total current assets

     11,196       10,769       10,213  

Property and equipment, at cost

     47,235       46,295       42,965  

Accumulated depreciation

     (24,520     (24,293     (23,208
  

 

 

   

 

 

   

 

 

 
     22,715       22,002       19,757  

Investments of insurance subsidiaries

     315       357       362  

Investments in and advances to affiliates

     249       243       232  

Goodwill and other intangible assets

     8,269       8,160       7,953  

Right-of-use operating lease assets

     1,834       1,770       —    

Other

     480       611       690  
  

 

 

   

 

 

   

 

 

 
   $ 45,058     $ 43,912     $ 39,207  
  

 

 

   

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

      

Current liabilities:

      

Accounts payable

   $ 2,905     $ 2,610     $ 2,577  

Accrued salaries

     1,775       1,669       1,580  

Other accrued expenses

     2,932       2,697       2,624  

Long-term debt due within one year

     145       148       788  
  

 

 

   

 

 

   

 

 

 

Total current liabilities

     7,757       7,124       7,569  

Long-term debt, less debt issuance costs and discounts of $239, $244 and $157

     33,577       34,097       32,033  

Professional liability risks

     1,370       1,349       1,275  

Right-of-use operating lease obligations

     1,499       1,440       —    

Income taxes and other liabilities

     1,420       1,349       1,248  

EQUITY (DEFICIT)

      

Stockholders’ deficit attributable to HCA Healthcare, Inc.

     (2,808     (3,565     (4,950

Noncontrolling interests

     2,243       2,118       2,032  
  

 

 

   

 

 

   

 

 

 

Total deficit

     (565     (1,447     (2,918
  

 

 

   

 

 

   

 

 

 
   $ 45,058     $ 43,912     $ 39,207  
  

 

 

   

 

 

   

 

 

 

 

8


HCA Healthcare, Inc.

Consolidated Statements of Cash Flows

For the Years Ended December 31, 2019 and 2018

(Dollars in millions)

 

     2019     2018  

Cash flows from operating activities:

    

Net income

   $ 4,145     $ 4,389  

Adjustments to reconcile net income to net cash provided by operating activities:

    

Increase (decrease) in cash from operating assets and liabilities:

    

Accounts receivable

     (326     (423

Inventories and other assets

     (158     (242

Accounts payable and accrued expenses

     396       698  

Depreciation and amortization

     2,596       2,278  

Income taxes

     250       74  

Gains on sales of facilities

     (18     (428

Losses on retirement of debt

     211       9  

Amortization of debt issuance costs and discounts

     30       31  

Share-based compensation

     347       268  

Other

     129       107  
  

 

 

   

 

 

 

Net cash provided by operating activities

     7,602       6,761  
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchase of property and equipment

     (4,158     (3,573

Acquisition of hospitals and health care entities

     (1,682     (1,253

Disposition of hospitals and health care entities

     61       808  

Change in investments

     25       57  

Other

     34       60  
  

 

 

   

 

 

 

Net cash used in investing activities

     (5,720     (3,901
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Issuance of long-term debt

     6,451       2,000  

Net change in revolving credit facilities

     (560     (640

Repayment of long-term debt

     (5,324     (1,704

Distributions to noncontrolling interests

     (542     (441

Payment of debt issuance costs

     (73     (25

Payment of dividends

     (550     (487

Repurchase of common stock

     (1,031     (1,530

Other

     (142     (248
  

 

 

   

 

 

 

Net cash used in financing activities

     (1,771     (3,075
  

 

 

   

 

 

 

Effect of exchange rate changes on cash and cash equivalents

     8       (15
  

 

 

   

 

 

 

Change in cash and cash equivalents

     119       (230

Cash and cash equivalents at beginning of period

     502       732  
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 621     $ 502  
  

 

 

   

 

 

 

Interest payments

   $ 1,914     $ 1,744  

Income tax payments, net

   $ 849     $ 872  

 

9


HCA Healthcare, Inc.

Operating Statistics

 

     Fourth Quarter     For the Years
Ended December 31,
 
     2019     2018     2019     2018  

Operations:

        

Number of Hospitals

     184       179       184       179  

Number of Freestanding Outpatient Surgery Centers

     123       123       123       123  

Licensed Beds at End of Period

     49,035       47,199       49,035       47,199  

Weighted Average Licensed Beds

     48,911       47,159       48,480       46,857  

Reported:

        

Admissions

     540,194       503,371       2,108,927       2,003,753  

% Change

     7.3       5.2  

Equivalent Admissions

     933,996       865,255       3,646,335       3,420,406  

% Change

     7.9       6.6  

Revenue per Equivalent Admission

   $ 14,478     $ 14,186     $ 14,079     $ 13,647  

% Change

     2.1       3.2  

Inpatient Revenue per Admission

   $ 14,842     $ 14,555     $ 14,436     $ 13,927  

% Change

     2.0       3.7  

Patient Days

     2,601,233       2,438,963       10,268,899       9,732,115  

% Change

     6.7       5.5  

Equivalent Patient Days

     4,497,531       4,192,482       17,754,926       16,612,720  

% Change

     7.3       6.9  

Inpatient Surgery Cases

     145,584       138,625       566,635       548,220  

% Change

     5.0       3.4  

Outpatient Surgery Cases

     266,483       256,240       1,009,947       971,537  

% Change

     4.0       4.0  

Emergency Room Visits

     2,350,988       2,174,606       9,161,129       8,764,431  

% Change

     8.1       4.5  

Outpatient Revenues as a Percentage of Patient Revenues

     38.7     38.2     38.7     38.2

Average Length of Stay (days)

     4.815       4.845       4.869       4.857  

Occupancy

     57.8     56.2     58.0     56.9

Same Facility:

        

Admissions

     511,928       488,870       2,002,001       1,947,437  

% Change

     4.7       2.8  

Equivalent Admissions

     878,468       836,457       3,431,430       3,316,485  

% Change

     5.0       3.5  

Revenue per Equivalent Admission

   $ 14,343     $ 14,183     $ 13,979     $ 13,664  

% Change

     1.1       2.3  

Inpatient Revenue per Admission

   $ 14,859     $ 14,610     $ 14,469     $ 13,945  

% Change

     1.7       3.8  

Inpatient Surgery Cases

     137,263       134,471       535,727       530,148  

% Change

     2.1       1.1  

Outpatient Surgery Cases

     251,693       247,362       954,207       938,865  

% Change

     1.8       1.6  

Emergency Room Visits

     2,245,196       2,104,915       8,745,775       8,503,941  

% Change

     6.7       2.8  

 

10


HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

Operating Results Summary

(Dollars in millions, except per share amounts)

 

     Fourth Quarter     For the Years
Ended December 31,
 
     2019     2018     2019     2018  

Revenues

   $ 13,523     $ 12,274     $ 51,336     $ 46,677  

Net income attributable to HCA Healthcare, Inc.

   $ 1,071     $ 1,064     $ 3,505     $ 3,787  

Gains on sales of facilities (net of tax)

     —         (6     (13     (324

Losses on retirement of debt (net of tax)

     —         —         162       7  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt (a)

     1,071       1,058       3,654       3,470  

Depreciation and amortization

     694       581       2,596       2,278  

Interest expense

     438       446       1,824       1,755  

Provision for income taxes

     333       242       1,143       844  

Net income attributable to noncontrolling interests

     202       181       640       602  
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA (a)

   $ 2,738     $ 2,508     $ 9,857     $ 8,949  
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA margin (a)

     20.3     20.4     19.2     19.2

Diluted earnings per share:

        

Net income attributable to HCA Healthcare, Inc.

   $ 3.09     $ 3.01     $ 10.07     $ 10.66  

Gains on sales of facilities

     —         (0.02     (0.04     (0.91

Losses on retirement of debt

     —         —         0.47       0.02  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt (a)

   $ 3.09     $ 2.99     $ 10.50     $ 9.77  
  

 

 

   

 

 

   

 

 

   

 

 

 

Shares used in computing diluted earnings per share (millions)

     346.791       352.876       348.226       355.303  

 

(a)

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that gains on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.    

 

11


HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

2020 Operating Results Forecast

(Dollars in millions, except per share amounts)

 

     For the Year Ending
December 31, 2020
 
     Low      High  

Revenues

   $ 53,500      $ 55,500  

Net income attributable to HCA Healthcare, Inc. (a)

   $ 3,875      $ 4,150  

Depreciation and amortization

     2,790        2,820  

Interest expense

     1,760        1,780  

Provision for income taxes

     1,160        1,225  

Net income attributable to noncontrolling interests

     665        675  
  

 

 

    

 

 

 

Adjusted EBITDA (a) (b)

   $ 10,250      $ 10,650  
  

 

 

    

 

 

 

Diluted earnings per share:

     

Net income attributable to HCA Healthcare, Inc.

   $ 11.30      $ 12.10  

Shares used in computing diluted earnings per share (millions)

     342.200        342.200  

The Company’s forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.

 

(a)

The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.

 

(b)

Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles (“GAAP”). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.     

Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.    

 

12

EX-101.SCH 3 hca-20200128.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 hca-20200128_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 hca-20200128_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g8792572.jpg GRAPHIC begin 644 g8792572.jpg M_]C_X 02D9)1@ ! 0$ R #( #_X@Q824-#7U!23T9)3$4 0$ Q(3&EN M;P(0 !M;G1R4D="(%A96B 'S@ " D !@ Q !A8W-P35-&5 !)14,@ M0 9&5S8P 2D! M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! M LL"U0+@ NL"]0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H# MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P M!/X%#044%]@8&!A8&)P8W!D@& M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0) MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X- M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3 M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8# M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9 M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC M',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@ M;""8(,0@\"$<(4@A=2&A(B>K)]PH#2@_*'$H MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT, M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<-]1B)&9T:K1O!'-4=[1\!( M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4 MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5 M6^5<-5R&7-9=)UUX7&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I( M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5&YXS'DJ>8EYYWI& M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*" M](-7@[J$'82 A..%1X6KA@Z&I+CDTV3MI0@E(J4 M])5?EAMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H M4JC$J3>IJ:H_ MR#W(O,DZR;G*.,JWRS;+MLPUS+7--:6YQ_GJ>@RZ+SI1NG0ZEOJ MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ M_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0# M! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1 M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 M Q$ /P#ZR_X*<_\ !=OX^_\ !-GQA*_B3]E 6?@*\UN]TG0?%5QXTCO+774B MD;R)F6V@;[%)/"OFK;SMYA D W>5(1E_L-?\'*&FZO\ \$]+[XO_ +0T.@VO MBJ\\>W'@_P ->%_ 6F3'4/$(BL].G8P6US=2%FC:])DE:5(U#0I_K9(UE]F_ MX.;?#VGZU_P1<^+5S>6-G=W&DSZ)=V,LT*R/93'6;*$R1$C*.8II8]RX.R5U MZ,0?EG_@SQ_9B\#W/[+WCSXMW/A_3;SQ\/&(E3LU*VC>NW=NU[Z_@>;*=6.)]DI:-7U MMH<+^T=_PY%"%_T=\%'?:R_(/TH_X)+_\ !6[P3_P5H^#VL:]X;TG4?"_B+PI/!:>( M-!OIHYY+%YH]\4L4J?ZVWD*S(CLD;EK>7,:@ M[?^U7^SUX;_:M_9N\;?#GQ M;;?:/#_C#1[C3;HI%%)-;;T.RXA\U'19X9 DL3LC;)(T8#*BOP"_X,Y_$FH6 MW_!1/XB:1%?7D>DWWPYN;RXLEF86\\T.IZI^S_^ MS;\+[G]H;XIVJS'61:ZQ%IFDZ&\/,D+W,BE'D0 K(6:..-WC3S'EWQ)WW_!? M/]N:\_8(_P"":7C/Q)H.IC2?&GBF2'PIX9N/+G+QWEWN\V2-XB#%-%9QWD\< MCL%$D$>=Q(1_S\_X-1/C=^S_ /LN?LJ_$;Q#X\^)WPQ\!^/O$_BK^SW@\1>* M[/3;J;2[6T@DMF2&>52$\^ZO!O5<.5 )/E@+RX/ IX:6+G'FL[):ZON[:V7E MNS6M7?M51B[=6_(]_P#VHO\ @I?^W=_P3+\'V_Q"^-OP9^!?Q)^&[1M;WTGP MYO\ 5-/N-"N69! ]W-=&XV0L2R;EMV3>44RHS1K)]A?L1?\ !3;P3_P4:_9: MUKXC_"&RU+6-1T=;FWE\+:I)#I^IPWT:,T-M,V^2*,3@(4F#O'M?DADD1<_X MV?M[_LF_'?X,^+O ^M_M%? >71?&6BWFA7Z#X@Z8FZWNH'@D&4N5<91SRK*P M[$'FOPZ_X-*/VCW^%'_!3*\\#W%UK7]F_%7PS=V$-G:D&S;4+,"^BN+A2PXC MMH;^-&4,P:YQ@*[,O1#!QQ&%J573Y9T[/2Z37IY:ZKR(G7=.M&'-=2_!GVI^ MU%_P=0?$;]BSXKS^!_BC^Q]J7@_Q-# ET+2[^(:.MQ Q95FAECTYHIHBR.OF M1LR[HW7.Y6 ^^?\ @FA^VG\4/VY?AC)XS\=? N3X.^&=6T[3M6\*7C^+[;73 MXEM;I)9#((XHHI+8(BP,!*H+BX! &TU\0_\ !X)^S#RD\L -'$D$RVJ;L[OL+'<>0%B*.'GEZ MQ-&FE*]I:R=O2[ZZ;WW^9-*I46)=*//MEQI&G75M90Z?I[P?VAJD\\JHL5M'-+&LLBH9)F4-D102M@A#70?L>_ MM7>$_P!N#]FSPG\5/ \UY-X9\76AN+9;N P7-M(DCPS02KR/,BFCDC8J60F, ME&=2K'\I/^#GJ;QI^VS\1;7X#_#>:WO(_@OX%O\ XS^,K%IHC]LCCECL[>*+ M:K2"\@@ENIO)9HQ)%= KYCB-31_X,Y?VO9O$'PU^*'P/U;4H9)/#=U#XK\/6 MTUQ+)&^M=.TSQLGCZVM8 M]1GFM5F97LTM9IK<+)YT0:7"N8L@_.H/H'_!,?\ X*.?%[]O?38?%'B_]FO4 MO@[\,M4T-M7T?Q1J'C""^.JOYD(BC6R:W@N%BEA>29+AE\MDC!4L)%->(_\ M!P+HB?MB?&+]EO\ 9/M?.:3XK>.6\1^(9;'6HK.[L]$TRWD^U Q,K;C)!/;/P7"TVM7'@Z]B:*-(V:6R*8O457! M!)M#< !?GR?D^?;6;A1=&E#D2E/K>6BO:]KVNW?RTV*O4524N9N*Z66^]MCY MV\+_ /!9?XN?\%#?'_B'P[^QG\(='\0>'?#=U_9]_P#$WXB7LEAX<@N5:5RL M=G 1=7,%WU;1_%OP]^)6C3Z>FJZ-GW=[OSO?\-NENIG1E*M M2YH3][Y:>5BC_P $]OVAM:_:O_8B^%_Q(\26^E6>O>-/#]MJM_#ID4D5G%+( MN6$22.[JGH&=C[FBN1_X)+?L8:]_P3Z_X)^> ?A#XDU32=;UKPFVIM<7NF^9 M]EF^U:G=WB;/,56X2X53D#E3CC!HKP\2X*M)4_AN[>E]#LI\W*N;<\E_X.6O M^4)_QJ^FA_\ I^TZO"_^#.W_ )1F>.?^RG7_ /Z:M)K6_P"#E_\ ;V^#\W_! M,;XG?#'3OB)X/UWX@:WJ^F:'_8&DZS:WNHZ=<6VI07<_VJWCD,L"HEG*K,ZC M$C1H<%A7@_\ P:F?\% _@M^SS^Q9X_\ OQ"^)G@SP#XAC\:3:_''XEU>#28 M;JTGL;*!&BEN'1)&$EI*&5264%"1A@:^@I4:G]D27*_COMTLM3SZE2/UZ.OV M;?F?MUK'_()NO^N+_P C7\WG_!G;_P I-/'/_9,+_P#].NDU^\/[6G[?GP<_ M8\\-ZW_PL+XC>#?#NL6.A3ZW%H-WK5K!K.I6RK*%-M:22++,TCQ21H$!WNI4 M'(./YW?^#73]JKX>_LF_\%&M:U/XD>+-(\%Z3XE\$7N@V6H:K,+>S^UM>V%P MJ2S-^[A!CMI2'D95R N=S*"951J/ XBT7JE;3??8,9./UBEKU?Z'Z;_\'?\ MX>U+6_\ @F#X7N;'3[Z]M=(^(VG7>H36\#21V$!T_4H1+,P&(XS--#&&; +S M1KG+ 'RO_@U3_8\^#?[1?_!/3Q?J_C_X4_#/QSKEE\0KVQBOO$'AFQU.[CMQ MIVFR+$LDT3.(PTDA"@X!9CC)-?I_^U_^SOX1_P""D_[#?BSP'_:VFZAX9^)> M@K)I.MV(](CM4AGU"*VN)DM=5T^68(+A$;[6L9$BPR MK+)E@RJR:9>YU\OGA:3M4B[I;-KR_'\.Y.(2IXF-6?PM6/Z'O^'7/[,O_1NO MP)_\('2O_C%;WPS_ &"_@7\%O&UGXE\&_!?X3^$_$>F[_LFJZ-X1T^POK7>C M1OY&?[)Z>0+6\.J#]]Y/ M_(/\G[9]_G_4_<_>?ZOYZ\O_ &*_VF?BW_P59_;HT7XV>"IO%'PU_90^'NG7 MVCZ?9ZNGEW'Q5U"==DUQ]F4E$MK:1(]D[%RK0.D9W3W4=MY'L<7R2E5;C%;W MNOEYM]OOT.WGHW2A9ORM]Y]A?MN_LTV/[8W[(GQ&^%]]'I;+XVT"[TRUEU"U M%U;V-XT9-K=E#U:"X$4RD?,KQ*P((!K\&O\ @T+_ &FQ\(?VV/B!\,=7O-)T MO3_B%X=^W1I>YCO)M1TR1G2&(E@H M;C4))%*EB+=2"H1@W]&]?RY_\ !;C] MC3Q=^SU_P7!U_P .?#>3R]4_:#E%[X?A741YMXWB/S]-OK::24*D2SW37]+[CFQR<)PKKH[?>?L9_P0STYOVE]$^/ M'[46K++<1_M,>,[AM&@NUA5T\-:2TNFZ;!&C@MKFUN MV5^2UOM9D.67^E_]G[X+Z3^SA\"?!?P^T&2]N-%\#Z'9:!8S7C(US-#:P) C MRE%1#(RH"Q55!8D@#I7XB?\ !Y%^R5_9_B[X4_'#3[>Z9=2MYO!FM2%D%M&\ M1>[L,*$W&619+\.S.1MMX@%7:2VF4XJ%7%U*,OAJ*R7HK+[EH3C*+C1C46\7 M?_/\3["_8WM7_;G_ ."]GQ\^-$UJ&\(_L]Z1%\(O#$\VBSP?:-2$LDFHR)<. M^QIK:;[;$P1?F@U"W;"Y#2?HAX]^(.@_"[PQ-K7B;6M)\/Z/;RPPRW^IWD=I M;1/-*D,2M)(0H9Y9(XU!.6=U49) KY!_X-[OV:(OV;?^"5/PTDE6&;7?B1;- MX\UF^2>25M1FU+;-!*^]CB1;(6<3;< F$G&XL3D?\'+[!?\ @B7\:MR[E8Z$ MI'UU[3A7FUHJMC(T$]$U!/R6E_F[OYG5"3A1=1K75_K_ , ^?OVZ_P#@TF^$ M_P"T!XUU3Q5\)?%EY\(=1U:YEO;C0_[,34= 5F3/EVL*O#)9HTN6(#RQH&VQ MQ(BJH_+OXU_\$]/VSO\ @@[XQ/Q!TF\UG0]'M6MOM/C'P1J,EYH<^)(F2&^1 MD1O)\^2./9>VZPRN=JB3//[)_P#!&W_@N)X1_:,^%>B_"_XV^*+/P1^T9X7N M#X1W M8C")FVO>2%HTEMP4E^T+-M@6,+CL_P#@O9^WS\(? MV-?B!X8N=#T'PK!-%FWSNCMX9(Y)3<. M%0-;%$8S&.-O4P^88ZC66$KKG5[6:OIW3ZKS=SCJ8>A4INM3?*]].YV__!%[ M_@I--_P5'_8DL?B#J&DQ:+XHTC4Y_#OB.VMD9;,W\,<4IDM]S,WE/#<0/AB2 MC.Z9;9O8KS3_ (-L_P!B;QE^P]_P34L]-\=V.H:+XF\>:_=>+[C1+ZT%O=Z' M'-#;VT$$P#L?,:&TCG97$;QFX\IXU>)LE>#C_91Q$XT?AN['H8?F=.+J;V/I MOQ;_ ,$Y_P!GSQ_XHU#7->^!/P;US6M6N'N[[4-0\%:;$L[L MQ)+,222236)F$8>2 M1@H. 78XR37)_P##KG]F7_HW7X$_^$#I7_QBBBB.(JQ5HR:7JQ^SB]6CV;PK MX5TOP+X9T_1=%TZQT?1M'MH[*PL+*W2WM;*"-0D<,4: *D:*H554 * *X MW]H']D_X9_M7:+9Z?\2O 7A/QU::K;%&$8_" MK#J\_P#&O[*GPU^(_P 9_#_Q&U[P+X5U;Q[X5B$&D>(+K3(9=1L(P794CF*[ MPJM+(RC.$:1V7!8DE%3&36J*:3W/0 -HQ7)_&SX$>#?VD?A]=>%/'GAO2/%G MAN\DCEGTW4[=9[>5XV#HQ5N,JP!'N***E2:U0-75F=-I^GPZ38PVMK#';VUN M@CBBC0(D2 8"J!P !P . *QOB?\ "KPO\;? ]]X8\9>'-!\6^&]3\O[9I.LZ M?#?V-WY2XMM7NC-JNJ6321&%Q!=WCS3PJT992L;JI#OQ\ ?S9**V^M5E#V:D^7M=V^XGV<+\UE<^C0,4445B6?_V0$! end GRAPHIC 7 g879257g0128041136734.jpg GRAPHIC begin 644 g879257g0128041136734.jpg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end EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d879257d8k.htm d879257dex991.htm hca-20200128.xsd hca-20200128_lab.xml hca-20200128_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false ZIP 10 0001193125-20-016154-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-016154-xbrl.zip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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information
Jan. 28, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000860730
Document Type 8-K
Document Period End Date Jan. 28, 2020
Entity Registrant Name HCA HEALTHCARE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-11239
Entity Tax Identification Number 27-3865930
Entity Address, Address Line One One Park Plaza
Entity Address, City or Town Nashville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37203
City Area Code (615)
Local Phone Number 344-9551
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $.01 par value per share
Trading Symbol HCA
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d879257d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d879257d8k.htm" ] }, "labelLink": { "local": [ "hca-20200128_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hca-20200128_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hca-20200128.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hca", "nsuri": "http://www.hcahealthcare.com/20200128", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d879257d8k.htm", "contextRef": "duration_2020-01-28_to_2020-01-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d879257d8k.htm", "contextRef": "duration_2020-01-28_to_2020-01-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20200128/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 14 d879257d8k_htm.xml IDEA: XBRL DOCUMENT 0000860730 2020-01-28 2020-01-28 false 0000860730 8-K 2020-01-28 HCA HEALTHCARE, INC. DE 001-11239 27-3865930 One Park Plaza Nashville TN 37203 (615) 344-9551 false false false false Common Stock, $.01 par value per share HCA NYSE false XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }